Exact Sciences Stock Surges to 52-Week High

Exact Sciences Corporation has achieved a significant milestone, with its stock reaching a 52-week high of $73.09. This surge reflects a robust annual performance, with a 36.93% increase over the past year and notable gains year-to-date and in the last six months. Investor confidence remains high, bolstered by the company's recent Q3 2025 financial disclosures.

The company reported a strong third quarter for 2025, with earnings per share of $0.24, significantly beating the forecasted loss. Revenue also exceeded projections, reaching $851 million. This financial success was complemented by a 22% year-over-year growth in its core screening business, attributed to advancements in Cologuard rescreens and health plan care gap orders. Several financial firms maintained a Buy rating and raised their price targets following these results.